Inhibition of tigar increases exogenous p53 and cisplatin combination sensitivity in lung cancer cells by regulating glycolytic flux

HIGHLIGHTS

  • who: Jiaying Fu and collaborators from the Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, China have published the paper: Inhibition of TIGAR Increases Exogenous p53 and Cisplatin Combination Sensitivity in Lung Cancer Cells by Regulating Glycolytic Flux, in the Journal: (JOURNAL)
  • how: The authors performed the same treatment in the 16HBE cell lines of bronchial epithelial_cells and the flow cytometry results showed that compared with the cisplatin treatment the combination treatment of p53 and cisplatin did not cause a further apoptosis of the 16HBE cells . To investigate the pathway through which . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?